


TSE : 4568

Reference Data

Consolidated Financial Results for Q3 FY2010



Daiichi-Sankyo

January 31, 2011

Daiichi Sankyo Co., Ltd.
<http://www.daiichisankyo.com>

(This page is intentionally left blank)



Daiichi-Sankyo

Reference Data

Consolidated Financial Results for Q3 FY2010

[1]	Summary of Income Statement	P1
[2]	Currency Rate	P2
[3]	Sales of Global Products	P3
[4]	Overseas Sales	P4
[5]	Geographic Segment Information	P4
[6]	Status of Major Companies	P5
[7]	Number of Employees	P9
[8]	Consolidated Balance Sheets	P10
[9]	Consolidated Statements of Cash Flows	P12
[10]	R&D Pipeline	P13

<Historical Data>

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.

1. Summary of Income Statement

< Consolidated Income Statement >

(Billions of yen)

	FY2010 Results					Details (YoY Changes)
	Q3	Q3 YTD	YoY Changes			
Net Sales	<-2.3> 100.0	249.2	<3.1> 100.0	748.1	22.4	Ranbaxy Group: ¥+31.8 bil Olmesartan: ¥+6.8 bil, Loxonin: ¥+4.5 bil Levofloxacin: ¥-13.5 bil, Pravastatin: ¥-9.3 bil [Decrease by yen appreciation: Approx. ¥-23.0 bil]
Cost of Sales	29.9	74.6	28.5	213.1	0.4	Cost to sales ratio: -0.8 Points (Impact of Ranbaxy: -1.1 Points)
SG&A Expenses	57.8	144.1	55.4	414.4	-8.6	Decrease by yen appreciation: Approx. ¥-18.0 bil
R&D Expenses	21.3	53.0	19.0	142.3	0.6	Initial payment related to in-licensing ¥ 8.2 bil
Other Expenses	36.5	91.1	36.4	272.0	-9.2	
Operating Income	<-22.2> 12.3	30.5	<33.9> 16.1	120.6	30.6	
Non-operating Income		7.5		17.6	-1.5	Gain on valuation of Ranbaxy's forex derivatives, etc.
Non-operating Expenses		0.0		7.6	-10.9	Foreign exchange losses of Ranbaxy, etc.
Ordinary Income	<-1.1> 15.2	38.0	<44.1> 17.5	130.6	40.0	
Extraordinary Gains		0.9		8.5	4.7	Gains on sales of non-current assets and investment securities, etc.
Extraordinary Losses		2.2		8.3	4.8	Loss on valuation of investment securities and stocks of subsidiaries / affiliates, etc.
Income before taxes and minority interests	14.7	36.7	17.5	130.9	39.9	
Income Taxes		8.0		42.7	-10.1	Tax rate: 32.6%
Minority Interests		1.2		8.5	9.5	
Net Income	<33.8> 11.0	27.5	<103.0> 10.6	79.7	40.4	

< Daiichi Sankyo Group >

	FY2010 Results		
	Q3 YTD	YoY Changes	
Net Sales	<-1.5> 100.0	614.1	-9.4
Cost of Sales	25.1	154.2	-1.1
SG&A Expenses	59.0	362.4	-10.4
R&D Expenses	21.9	134.4	-0.5
Other Expenses	37.1	228.0	-9.9
Operating Income	<-2.2> 15.9	97.5	2.1
Non-operating Income		6.3	-0.3
Non-operating Expenses		3.6	-1.1
Ordinary Income	<-3.0> 16.3	100.2	2.9
Extraordinary Gains		6.0	2.2
Extraordinary Losses		5.9	2.3
Income before taxes and minority interests	16.3	100.3	2.7
Income Taxes		33.7	-20.8
Minority Interests			
Net Income	<-54.4> 10.8	66.6	23.5

< Ranbaxy Group >

	FY2010 Results		
	Q3 YTD (Jan-Sep)*	YoY Changes	
Net Sales	<31.3> 100.0	134.2	32.0
Cost of Sales	43.8	58.7	1.4
SG&A Expenses	36.4	48.9	3.3
R&D Expenses	6.9	9.2	2.4
Other Expenses	29.6	39.7	0.9
Operating Income	<-> 19.8	26.6	27.4
Non-operating Income		11.9	-0.5
Non-operating Expenses		3.8	-9.9
Ordinary Income	<-> 25.9	34.7	36.8
Extraordinary Gains		5.2	5.2
Extraordinary Losses		2.2	2.2
Income before taxes and minority interests	28.1	37.7	39.8
Income Taxes		10.8	10.2
Minority Interests		0.2	0.1
Net Income	<-> 19.9	26.7	29.6

< Inter-Segment Transactions >

	FY2010 Results	
	Q3 YTD	YoY Changes
Net Sales	-0.2	-0.2
Cost of Sales	0.1	0.1
SG&A Expenses	3.1	-1.4
R&D Expenses	-1.3	-1.3
Other Expenses	4.4	-0.1
Operating Income	-3.4	1.1
Non-operating Income	-0.7	-0.7
Non-operating Expenses	0.1	0.1
Ordinary Income	-4.2	0.3
Extraordinary Gains	-2.6	-2.6
Extraordinary Losses	0.2	0.2
Income before taxes and minority interests	-7.1	-2.6
Income Taxes	-1.8	0.6
Minority Interests	8.3	9.5
Net Income	-13.6	-12.6

* Due to the difference in fiscal year-end, Ranbaxy's results included in the Group's Q3 YTD FY2010 are those of Jan-Sep 2010.

(Billions of yen)

	FY2010 Forecast				Details (From Oct. Forecast)
	Full Year	YoY Changes	From Oct. Forecast		
Net Sales	<1.4> 100.0	965.0	12.9	-15.0	Performance of certain overseas subsidiaries and OTC business below expectation
Cost of Sales	29.0	280.0	2.0	-12.0	
SG&A Expenses	58.5	565.0	-13.6	-23.0	Delay in R&D expense implementation
R&D Expenses	20.1	194.0	-2.8	-16.0	
Other Expenses	38.4	371.0	-10.8	-7.0	
Operating Income	<25.6> 12.4	120.0	24.5	20.0	
Non-operating Income / (Expenses)		5.0	-2.6	5.0	
Ordinary Income	<21.2> 13.0	125.0	21.9	25.0	
Extraordinary Gains / (Losses)		-3.0	2.7	-5.0	
Income before taxes and minority interests	12.6	122.0	24.6	20.0	
Income Taxes / Minority Interests		52.0	-3.5	5.0	
Net Income	<67.3> 7.3	70.0	28.1	15.0	

2. Currency Rate

	FY2009	FY2010		FY2010 Original Forecast	
	Q3 YTD Results	Q3 YTD Results	Full Year Forecast	Full Year Forecast	Annual impact of one yen change in currency rate
USD / Yen (average)	93.6	86.5	84.9	90.0	Net Sales ¥2.5 billion Operating Income ¥0.2 billion
EUR / Yen (average)	133.0	113.3	112.5	120.0	Net Sales ¥0.7 billion Operating Income ¥0.1 billion

* We do not revise forecast by company and product line.

3. Sales of Global Products

	FY2010 Results				(Billions of yen)	
	Q3	Q3 YTD	Progress	YoY Changes	FY2010 Forecast *	YoY Changes
Olmesartan <antihypertensive>	<0.8> 65.2	<3.8> 186.8	71.9%	6.8	<9.1> 260.0	21.7
Olmetec (JPN)	<3.5> 23.0	<6.1> 64.7	75.3%	3.7	<11.4> 86.0	8.8
Rezaltas (JPN)	<-> 1.3	<-> 3.2	64.4%	3.2	<-> 5.0	5.0
Benicar HCT / Benicar (US)	<-9.4> 20.6	<-6.4> 62.7	70.1%	-4.3	<0.6> 89.5	0.6
Azor (US)	<-5.3> 3.5	<8.2> 10.7	81.9%	0.8	<1.7> 13.0	0.2
Tribenzor (US)	<-> 0.5	<-> 1.2	-	1.2	<-> -	-
Olmetec Plus / Olmetec (EU)	<-1.6> 10.1	<-4.2> 27.3	66.6%	-1.2	<2.7> 41.0	1.1
Sevikar (EU)	<5.7> 2.3	<48.2> 6.3	66.8%	2.1	<50.0> 9.5	3.2
Other subsidiaries / Export, etc.	<-6.2> 3.5	<8.1> 10.2	63.5%	0.8	<21.8> 16.0	2.9
Levofloxacin <synthetic antibacterial>	<-18.3> 18.1	<-20.6> 51.9	74.2%	-13.5	<-19.7> 70.0	-17.2
Cravit (JPN)	<-14.5> 9.3	<-23.8> 24.6	74.5%	-7.7	<-24.4> 33.0	-10.6
Export, etc	<-36.5> 3.2	<-27.2> 11.8	74.0%	-4.4	<-24.8> 16.0	-5.3
Royalty	<-16.4> 3.4	<-17.2> 9.1	72.6%	-1.9	<-14.3> 12.5	-2.1
Other subsidiaries	<2.0> 2.1	<9.1> 6.4	75.7%	0.5	<10.7> 8.5	0.8
Pravastatin <antihyperlipidemic>	<-21.8> 11.6	<-20.8> 35.3	80.1%	-9.3	<-20.0> 44.0	-11.0
Mevalotin (JPN)	<-22.0> 10.0	<-19.6> 30.3	81.9%	-7.4	<-19.9> 37.0	-9.2
Other subsidiaries / Export, etc.	<-20.9> 1.6	<-27.5> 5.0	70.9%	-1.9	<-20.6> 7.0	-1.8
Prasugrel (alliance revenue) <antiplatelet>	<-> 1.5	<-> 3.3				
Effient (US)	<-> 1.1	<-> 2.2				
Efient (EU)	<-> 0.4	<-> 1.1				

Forecast of prasugrel is not disclosed.

Total global sales of prasugrel by Eli Lilly and Company for Apr-Dec 2010 is approximately USD 106 mil, of which the U.S. sales is approximately USD 80 mil.

4. Overseas Sales

(Billions of yen)

	FY2010 Results				
	Q3		Q3 YTD		YoY Changes
Overseas sales	<-4.0>	115.8	<6.0>	374.4	21.3
Overseas sales ratio		46.5%		50.1%	
North America	<-0.3>	58.7	<13.2>	204.1	23.7
Europe	<-7.4>	27.0	<-10.8>	76.8	-9.3
Other	<-7.6>	30.1	<7.8>	93.6	6.8

5. Geographic Segment Information

(Billions of yen)

	FY2010 Results				
	Q3		Q3 YTD		YoY Changes
Net Sales	<-2.3>	100.0 249.2	<-3.1>	100.0 748.1	22.4
Japan	<-2.5>	57.2 142.6	<-1.8>	53.8 402.7	-7.5
North America	<2.1>	21.8 54.2	<17.0>	25.3 189.3	27.5
Europe	<-3.8>	9.6 23.9	<-6.5>	9.0 67.1	-4.7
India	<-9.7>	6.1 15.2	<12.9>	6.8 50.6	5.8
Other	<-5.3>	5.3 13.2	<3.6>	5.1 38.3	1.3
Operating income	<-22.2>	30.5	<-33.9>	120.6	30.6
Japan		17.8		66.7	
North America		8.4		31.8	
Europe		3.2		7.9	
India		-1.1		14.5	
Other		1.9		3.8	

6. Status of Major Companies * We do not revise forecast by company and product line.

6-1. Daiichi Sankyo Co., Ltd.

	FY2010 Results				FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
Total net sales of ethical pharmaceuticals	<-1.4> 116.8	<-0.8> 325.1	78.3%	-2.7	<-0.7> 415.0	2.7
Olmetec <antihypertensive>	<3.5> 23.0	<6.1> 64.7	75.3%	3.7	<11.4> 86.0	8.8
Rezaltas <antihypertensive>	<-> 1.3	<-> 3.2	64.4%	3.2	<-> 5.0	5.0
Calblock <antihypertensive>	<-0.6> 3.8	<2.1> 11.0	78.7%	0.2	<2.3> 14.0	0.3
Artist <antihypertensive>	<-0.9> 6.3	<-0.3> 18.3	81.2%	0.0	<-3.5> 22.5	-0.8
Mevalotin <antihyperlipidemic agent>	<-22.0> 10.0	<-19.6> 30.3	81.9%	-7.4	<-19.9> 37.0	-9.2
Kremezin <treatment for chronic renal failure>	<-1.0> 3.6	<1.1> 10.7	82.0%	0.1	<-2.6> 13.0	-0.3
Hanp <treatment for acute cardiac failure>	<-1.4> 2.6	<-3.0> 6.9	81.3%	-0.2	<-10.0> 8.5	-0.9
Livalo <antihyperlipidemic agent>	<5.8> 2.2	<7.8> 6.2	77.3%	0.4	<9.7> 8.0	0.7
Sunrythm <antiarrhythmic agent>	<-10.1> 2.9	<-8.2> 8.4	80.3%	-0.8	<-8.6> 10.5	-1.0
Fastic <antidiabetic agent>	<-11.5> 1.3	<-8.3> 3.8	76.1%	-0.3	<-3.2> 5.0	-0.2
Cravit <synthetic antibacterial agent>	<-14.5> 9.3	<-23.8> 24.6	74.5%	-7.7	<-24.4> 33.0	-10.6
Inavir <anti-influenza>	<-> 2.8	<-> 2.8	-	2.8	<-> -	-
Loxonin <anti-inflammatory analgesic>	<10.0> 14.7	<12.1> 41.5	81.4%	4.5	<8.6> 51.0	4.0
Urief <treatment for dysuria>	<9.2> 2.8	<9.8> 7.7	67.1%	0.7	<27.3> 11.5	2.5
Zyrtec <antiallergic agent>	<-0.3> 2.4	<-5.5> 6.2	78.0%	-0.4	<-16.3> 8.0	-1.6
Omnipaque <contrast agent>	<-8.5> 6.5	<-10.4> 19.5	85.0%	-2.3	<-15.6> 23.0	-4.3

* We do not revise forecast by company and product line.

6-2. Daiichi Sankyo Healthcare Co., Ltd

	FY2010 Results				FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
Daiichi Sankyo Healthcare Co., Ltd	<9.1> 13.2	<-2.5> 34.2	70.5%	-0.9	<10.9> 48.5	4.8
LuLu Series	<47.0> 4.2	<11.6> 9.3	80.4%	1.0	<16.8> 11.6	1.7
Gaster 10	<-2.7> 0.6	<-3.0> 1.6	59.2%	0.0	<27.0> 2.6	0.6
Daiichi Sankyo Ichoyaku series	<9.5> 1.1	<-3.1> 2.7	72.1%	-0.1	<4.6> 3.7	0.2
Patecs series	<-3.2> 0.5	<-17.4> 1.7	66.8%	-0.4	<4.4> 2.6	0.1
Transino	<-57.6> 0.1	<-26.1> 0.5	32.4%	-0.2	<56.0> 1.4	0.5

6-3. Daiichi Sankyo, Inc. (US)

	FY2010 Results				FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
Daiichi Sankyo, Inc. (DSI)	<0.6> 34.6	<1.2> 102.1	70.4%	1.2	<9.0> 145.0	12.0
mil USD	<10.3> 422	<9.4> 1,180	73.2%	101	<12.5> 1,611	178
Benicar / Benicar HCT <antihypertensive>	<-9.4> 20.6	<-6.4> 62.7	70.1%	-4.3	<0.6> 89.5	0.6
mil USD	<-0.5> 251	<1.2> 725	72.9%	9	<3.8> 994	37
Azor <antihypertensive>	<-5.3> 3.5	<8.2> 10.7	81.9%	0.8	<1.7> 13.0	0.2
mil USD	<4.6> 42	<17.0> 123	85.2%	18	<5.0> 144	7
Tribenzor <antihypertensive>	<-> 0.5	<-> 1.2	-	1.2	<-> -	-
mil USD	<-> 6	<-> 13	-	13	<-> -	-
Welchol <antihyperlipidemic / type 2 diabetes>	<7.6> 7.9	<7.5> 22.2	78.0%	1.5	<3.5> 28.5	1.0
mil USD	<17.8> 95	<16.2> 257	81.2%	36	<6.8> 317	20
Effient (alliance revenue) <antiplatelet>	<-> 1.1	<-> 2.2	-	-	<-> -	-
mil USD	<-> 13	<-> 25	-	-	<-> -	-

Forecast of Effient is not disclosed.

* We do not revise forecast by company and product line.

6-4. Luitpold Pharmaceuticals, Inc. (US)

	FY2010 Results				(Billions of yen) FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
Luitpold Pharmaceuticals, Inc. (LPI)	<-8.5> 11.5	<1.2> 39.9	84.9%	0.5	<-9.8> 47.0	-5.1
mil USD	<1.2> 142	<9.5> 461	88.3%	40	<-6.9> 522	-39
Venofer <treatment for iron deficiency anemia>	<-27.1> 5.8	<-8.9> 22.0	81.4%	-2.1	<-16.0> 27.0	-5.2
mil USD	<-18.5> 72	<-1.5> 254	84.6%	-4	<-13.4> 300	-46

6-5. Daiichi Sankyo Europe GmbH

	FY2010 Results				(Billions of yen) FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
Daiichi Sankyo Europe GmbH (DSE)	<-5.0> 18.1	<-9.7> 49.5	65.6%	-5.3	<-0.4> 75.5	0.3
mil €	<12.1> 161	<6.0> 437	69.5%	25	<-9.7> 629	56
Olmetec / Olmetec Plus <antihypertensive>	<-1.6> 10.1	<-4.2> 27.3	66.6%	-1.2	<2.7> 41.0	1.1
mil €	<16.1> 90	<12.5> 241	70.5%	27	<12.3> 342	37
Sevikar <antihypertensive>	<-5.7> 2.3	<48.2> 6.3	66.8%	2.1	<-50.0> 9.5	3.2
mil €	<24.9> 20	<73.9> 56	70.8%	24	<-64.0> 79	31
Evista <treatment for osteoporosis>	<-21.7> 1.6	<-29.9> 5.0	62.1%	-2.1	<-12.7> 8.0	-1.2
mil €	<-7.4> 15	<-17.7> 44	65.8%	-9	<-4.6> 67	-3

Alliance Revenue of Efient (Europe)

	Q3	Q3 YTD	Progress	YoY Changes
Efient <antiplatelet>	<-> 0.4	<-> 1.1	-	-
mil USD	<-> 5	<-> 13	-	-

Alliance revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include such revenue.

Forecast of Efient is not disclosed.

* We do not revise forecast by company and product line.

6-6. Asia, South and Central America (ASCA)

	FY2010 Results				(Billions of yen) FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
ASCA Total	<3.3> 6.8	<9.3> 19.8	70.7%	1.7	<8.6> 28.0	2.2
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<-6.3> 1.1	<4.3> 3.3	85.1%	0.1	<-4.9> 3.9	-0.2
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<10.5> 1.6	<25.0> 4.8	70.4%	0.9	<26.7> 6.7	1.4
Daiichi Sankyo Taiwan Ltd. (DSTW)	<13.5> 0.8	<1.2> 2.4	77.3%	0.0	<-0.5> 3.1	0.0
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<9.7> 1.0	<13.8> 2.9	60.7%	0.3	<39.4> 4.7	1.3
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<53.4> 0.3	<36.7> 0.8	61.6%	0.2	<55.1> 1.4	0.5
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<6.4> 1.4	<24.7> 3.9	69.0%	0.8	<19.0> 5.6	0.9
Daiichi Sankyo Venezuela, S.A. (DSVE)	<-25.1> 0.6	<-28.9> 1.7	60.3%	-0.7	<-30.6> 2.9	-1.3

6-7. Ranbaxy Laboratories Limited

	FY2010 Results				(Billions of yen) FY2010 Forecast *	
	Q3	Q3 YTD	Progress	YoY Changes	Full Year	YoY Changes
Ranbaxy Laboratories Limited	<-1.6> 35.4	<31.1> 134.0	81.2%	31.8	<12.6> 165.0	18.4

7. Number of Employees

	FY2009	FY2010	
	Mar-10	Sep-10	Dec-10*
Total Number of Employees	29,825	30,424	30,633
Japan	8,892	9,048	9,071
Overseas	20,933	21,376	21,562

	FY2009		FY2010			
	Mar-10	MRs	Sep-10	MRs	Dec-10*	MRs
Total Number of Employees	29,825		30,424		30,633	
<Japan>						
Daiichi Sankyo Co., Ltd. (DS)	6,028	2,400	6,182	2,400	6,087	2,400
Daiichi Sankyo Healthcare Co., Ltd (DSHC)	391	150	392	150	391	150
<US>						
Daiichi Sankyo, Inc. (DSI)	2,940	1,800	2,897	1,800	2,905	1,800
Luitpold Pharmaceuticals, Inc. (LPI)	611	80	633	80	655	80
<Europe>						
Daiichi Sankyo Europe GmbH (DSE)	2,432	1,340	2,470	1,370	2,480	1,370
<Asia / Latin America>						
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	490	178	495	183	481	172
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	565	247	584	267	595	273
Daiichi Sankyo Taiwan Ltd. (DSTW)	163	70	164	67	161	67
Daiichi Sankyo Korea Co., Ltd. (DSKR)	98	50	101	51	110	58
Daiichi Sankyo (Thailand) Ltd. (DSTH)	54	30	53	25	55	26
Daiichi Sankyo Hong Kong Ltd. (DSHK)	7	-	7	-	7	-
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	307	119	308	117	311	117
Daiichi Sankyo Venezuela, S.A. (DSVE)	141	84	161	86	156	81

	FY2009	FY2010	
	Mar-10	Sep-10	Dec-10*
Ranbaxy Group	12,995	13,405	13,358

* For overseas subsidiaries with different fiscal year-ends, figures as of Sep-10 are shown

(This page is intentionally left blank)

8. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	2010.3.31		2010.12.31		Change	Details
		%		%		
Current assets	819.8	55.0	861.4	58.5	41.6	
Cash and time deposits	101.0		126.4		25.4	Liquidity on hand (cash and time deposits + marketable securities + investment securities, etc.) Total ¥ 394.5 billion (¥ +36.2 billion from the end of fiscal 2009)
Trade notes and accounts receivable	211.9		226.2		14.3	
Marketable securities	236.5		260.2		23.7	
Inventories	143.2		142.9		-0.3	Breakdown of inventories as of December 31, 2010 Merchandise and finished goods: <u>¥ 92.5 billion</u> Work in process: <u>¥ 16.2 billion</u> Raw materials and supplies: <u>¥ 34.1 billion</u>
Deferred tax assets	87.0		73.1		-13.9	
Other current assets	41.8		34.4		-7.4	
Allowance for doubtful accounts	-1.7		-1.8		-0.2	
Non-current assets	669.8	45.0	610.5	41.5	-59.3	
Property, plant and equipment	249.5	16.8	237.6	16.1	-11.9	
Buildings and structures, net	126.6		118.7		-7.8	Transfer of Shizuoka Factory etc.
Machinery, equipment and vehicles, net	44.5		46.4		1.8	
Land	42.6		39.0		-3.6	
Construction in progress	22.3		21.4		-0.9	
Other, net	13.5		12.1		-1.4	
Intangible assets	180.9	12.1	161.6	11.0	-19.3	
Goodwill, net	73.8		72.6		-1.2	Amortization: U3 Pharma: <u>¥ -3.8 bil</u> , Ranbaxy: <u>¥ -1.8 bil</u>
Other intangible assets, net	107.1		89.0		-18.1	Forex loss, Amortization of Ranbaxy and sales rights of Evista in Europe, etc.
Investments and other assets	239.3	16.1	211.2	14.4	-28.1	
Investment securities	137.0		109.7		-27.3	Decrease in net unrealized gain on investment securities
Prepaid pension costs	3.9		1.5		-2.4	
Deferred tax assets	81.8		83.9		2.1	
Other	16.9		16.5		-0.5	
Allowance for doubtful accounts	-0.3		-0.3		0.0	
Total assets	1,489.5	100.0	1,471.8	100.0	-17.7	

<Liabilities and Net Assets>

(Billions of yen)

	2010.3.31		2010.12.31		Change	Details
		%		%		
Liabilities	600.0	40.3	578.7	39.3	-21.3	
Current liabilities	268.8	18.0	297.8	20.2	28.9	
Trade notes and accounts payable	66.5		70.2		3.6	
Short-term bank loans	20.0		30.9		10.9	
Convertible bond-type bonds with subscription rights to shares to be redeemed within one year	-		47.3		47.3	---- Change from long-term financing
Income taxes payable	10.6		11.3		0.7	
Allowance for sales returns	0.6		1.2		0.6	
Allowance for sales rebates	1.4		2.6		1.2	
Allowance for contingent losses	1.6		-		-1.6	
Other current liabilities	168.1		134.3		-33.7	
Long-term liabilities	331.2	22.2	280.9	19.1	-50.2	
Bonds payable	100.0		100.0		0.0	
Convertible bond-type bonds with subscription rights to shares	49.5		-		-49.5	---- Change to short-term financing
Long-term debt	121.4		124.4		3.0	
Deferred tax liabilities	29.2		25.2		-4.0	
Accrued employees' severance and retirement benefits	12.3		11.2		-1.2	
Accrued directors' severance and retirement benefits	0.1		0.2		0.0	
Other long-term liabilities	18.6		20.0		1.4	
Net assets	889.5	59.7	893.1	60.7	3.6	
Shareholders' equity	887.0	59.6	924.4	62.8	37.4	
Common stock	50.0		50.0		0.0	
Capital surplus	105.2		105.2		0.0	
Retained earnings	746.4		783.8		37.4	---- Dividends paid: <u>¥-42.2 bil</u> Net income: <u>¥+79.7 bil</u>
Treasury stock, at cost	-14.6		-14.6		0.0	
Valuation and translation adjustments	-31.3	-2.1	-71.0	-4.8	-39.6	
Net unrealized gain on investment securities	27.5		19.0		-8.5	
Deferred gains or losses on hedges	1.0		1.1		0.1	
Foreign currency translation adjustments	-59.8		-91.1		-31.3	
Subscription rights to shares	3.3	0.2	3.6	0.2	0.3	
Minority interests	30.5	2.0	36.1	2.4	5.5	
Total liabilities and net assets	1,489.5	100.0	1,471.8	100.0	-17.7	

9. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2009 Q3 YTD	FY2010 Q3 YTD	Change	
Income before income taxes and minority interests	91.0	130.9	39.9	
Depreciation	33.8	32.5	-1.2	
Amortization of goodwill	6.6	6.8	0.2	
(Gain) loss on valuation of derivatives	-10.5	-8.8	1.6	
(Gain) loss on valuation of investments securities	0.2	3.3	3.1	
(Gain) loss on sales of investment securities	-1.8	-3.0	-1.2	
(Gain) loss on sales and disposal of property, plant and equipment	-1.2	-3.6	-2.4	
(Increase) decrease in trade notes and accounts receivable	-35.2	-23.6	11.6	
(Increase) decrease in inventories	-4.0	-7.4	-3.4	
Increase (decrease) in trade notes and accounts payable	4.0	7.2	3.2	
Increase (decrease) in accounts payable and accrued expenses	-7.3	-13.1	-5.8	
Other, net	30.6	4.8	-25.8	--- FY2009: Refund of income taxes paid in FY2008
Income taxes paid	-25.4	-26.8	-1.4	
Cash flows from operating activities	80.8	99.2	18.5	
Net (increase) decrease in short-term operating assets	100.7	-75.6	-176.3	
(Acquisitions) / proceeds from sales of property, plant and equipment	-20.5	-17.2	3.3	
(Acquisitions) / proceeds from sales of investment securities	-0.5	8.0	8.5	
Proceeds from sales of investments in consolidated subsidiaries	0.0	5.6	5.6	--- Transfer of Shizuoka Factory
Purchases of investments in consolidated subsidiaries	-17.8	-9.5	8.3	--- FY2009: Acquisition of PharmaForce, etc FY2010: Acquisition of ROXRO PHARMA, etc
Other, net	0.9	1.9	1.0	
Cash flows from investing activities	62.8	-86.8	-149.6	
Net increase (decrease) in short-term bank loans and long-term debt	-139.5	16.1	155.6	
Proceeds from issuance of bonds	99.7	-	-99.7	
Dividends paid	-49.3	-42.3	7.0	
Other, net	-0.2	0.0	0.2	
Cash flows from financing activities	-89.3	-26.1	63.1	
Effect of exchange rate changes on cash and cash equivalents	0.7	-11.8	-12.6	
Net increase (decrease) in cash and cash equivalents	55.1	-25.5	-80.6	
Cash and cash equivalents, beginning of period	177.8	259.2	81.4	
Cash and cash equivalents, end of period	232.8	233.7	0.9	

(This page is intentionally left blank)

10. Major R&D Pipeline

Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1	Phase2
Cardiovascular diseases	Benicar/Olmetec Azor/Sevikar Tribenzor/Sevikar HCT Welchol Effient/Efient	DB-772d (Oral factor Xa inhibitor)	DU-176b(US/EU) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)
	Olmetec Rezaltas Calblock Artist Mevalotin Hanp Livalo Sunrythm Bepricor	CS-3150 (Antihypertensive)	CS-747(JP) (Prasugrel / ischemic stroke / anti-platelet agent)
Diabetes mellitus	Welchol Fastic		CS-1036(JP/Asia) (Glucose absorption inhibitor)
Cancer	Topotecin Krestin	CS-7017(JP/Asia) (Efatutazone / PPAR γ activator)	U3-1287(US/EU) (Anti-HER3 antibody)
		U3-1565(US) (Anti-HB-EGF antibody)	CS-1008(US/EU/JP/Asia) (Tigatuzumab / anti-DR5 antibody)
		U3-1287(JP) (Anti-HER3 antibody)	CS-7017(US/EU) (Efatutazone / PPAR γ activator)
			DE-766(JP) (Nimotuzumab / anti-EGFR antibody)
Infectious diseases	Levaquin / Tavanic Banan	CS-8958(US/EU) (Laninamivir / anti-influenza / co-development with Biota)	
	Cravit Inavir	CS-4771 (Sepsis)	
		DS-8587 (Broad spectrum antibacterial agent)	
Bone/Joint diseases	Loxonin		AMG 162(JP) (Denosumab / rheumatoid arthritis / anti-RANKL antibody)
Immunological allergic diseases	Zyrtec	CS-0777 (Immunomodulator)	SUN13834(US) (Chymase inhibitor)
Others	Venofer Evoxac Omnipaque Omniscan Visipaque Sonazoid Feron Urief	DS-5565 (Chronic pain)	SUN11031(US/EU) (Human ghrelin / cachexia)

★ Additional indications, new formulations etc.

Change from the announcement in October 2010

- # New(underline) AMG 162 (rheumatoid arthritis / JP / P2)、CS-3150(antihypertensive / P1)、U3-1565(anti-HB-EGF antibody / US / P1)、U3-1287(anti-HER3 antibody / JP / P1)
- # Change of Stage ☆CS-8635(Triple combination agent / EU / approved)、SUN Y7017(Alzheimer's type Dementia / JP / approved)、CS-747(ACS-PCI / JP / P3)、ARQ 197(c-Met inhibitor / US・EU / P3)
- # Discontinued etc. DB-772d(Oral factor Xa inhibitor / P1)

Phase3	Application
<p>★CS-747(US/EU/Asia) (Prasugrel / ACS-MM / anti-platelet agent)</p> <p>DU-176b(US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor)</p> <p>DU-176b(US/EU/JP/Asia) (Edoxaban / VTE / oral factor Xa inhibitor)</p> <p>CS-747(JP) (Prasugrel / ACS-PCI / anti-platelet agent)</p>	<p>★CS-8635(EU) (Olmesartan, Amlodipine, Hydrochlorothiazide combination)</p> <p>DU-176b(JP) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)</p>
<p>ARQ 197(US/EU) (c-Met inhibitor)</p>	
<p>★CS-8958(JP) (Laninamivir / prophylactic / anti-influenza)</p>	
<p>AMG 162(JP) (Denosumab / osteoporosis, breast cancer adjuvant / anti-RANKL antibody)</p>	<p>AMG 162(JP) (Denosumab / bone metastases of cancer / anti-RANKL antibody)</p>
<p>SUN11031(JP) (Human ghrelin / anorexia nervosa)</p> <p>★DD-723-B(JP) (Perflubutane / ultrasound contrast agent)</p>	<p>KMD-3213(China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia)</p> <p>SUN Y7017(JP) (Memantine / Alzheimer's type Dementia)</p>

1. Summary of Income Statement

(Billions of yen)

	FY2009									
	Q1		Q2		Q3		Q4		Full Year	
Net sales	<11.5> 100.0	227.1	<20.2> 100.0	243.4	<15.3> 100.0	255.1	<5.6> 100.0	226.4	<13.1> 100.0	952.1
Cost of Sales	27.5	62.5	30.7	74.7	29.6	75.4	28.9	65.4	29.2	278.0
Selling, general and administrative expenses	60.7	137.8	59.4	144.6	55.1	140.5	68.7	155.6	60.8	578.6
Research and development expenses	19.9	45.1	20.1	49.0	18.7	47.6	24.3	55.1	20.7	196.8
Other expenses	40.8	92.7	39.3	95.6	36.4	92.9	44.4	100.5	40.1	381.8
Operating income	<<33.1> 11.8	26.8	<11.5> 9.9	24.1	<7.6> 15.4	39.2	<<> 2.4	5.4	<7.5> 10.0	95.5
Non-operating income		3.9		10.9		4.3		9.1		28.2
Non-operating expenses		23.5		-10.1		5.1		2.1		20.6
Ordinary income	<<82.5> 3.2	7.2	<140.0> 18.5	45.1	<14.4> 15.0	38.4	<<> 5.5	12.5	<86.9> 10.8	103.1
Extraordinary gains		2.1		0.2		1.5		2.1		5.9
Extraordinary losses		0.7		0.3		2.5		8.1		11.6
Income before income taxes and minority interests	3.8	8.6	18.5	45.0	14.6	37.3	2.8	6.4	10.2	97.4
Income taxes		24.0		12.8		16.0		-2.7		50.0
Minority interests		-8.9		7.1		0.7		6.5		5.5
Net income	<<> -	-6.4	<182.7> 10.3	25.1	<<> 8.1	20.6	<-96.8> 1.2	2.6	<<> 4.4	41.9

	FY2010							
	Q1		Q2		Q3		Q3 YTD	
Net sales	<12.9> 100.0	256.4	<-0.4> 100.0	242.5	<-2.3> 100.0	249.2	<3.1> 100.0	748.1
Cost of Sales	25.0	64.1	30.7	74.4	29.9	74.6	28.5	213.1
Selling, general and administrative expenses	51.2	131.3	57.3	139.0	57.8	144.1	55.4	414.4
Research and development expenses	17.0	43.6	18.9	45.7	21.3	53.0	19.0	142.3
Other expenses	34.2	87.7	38.5	93.3	36.5	91.1	36.4	272.0
Operating income	<128.1> 23.8	61.1	<-20.6> 12.0	29.0	<-22.2> 12.3	30.5	<33.9> 16.1	120.6
Non-operating income		11.8		-1.7		7.5		17.6
Non-operating expenses		2.8		4.8		0.0		7.6
Ordinary income	<877.7> 27.3	70.1	<-50.0> 9.3	22.6	<-1.1> 15.2	38.0	<44.1> 17.5	130.6
Extraordinary gains		0.8		6.8		0.9		8.5
Extraordinary losses		4.8		1.3		2.2		8.3
Income before income taxes and minority interests	25.8	66.1	11.6	28.0	14.7	36.7	17.5	130.9
Income taxes		26.6		8.2		8.0		42.7
Minority interests		6.5		0.8		1.2		8.5
Net income	<<> 12.9	33.1	<-24.1> 7.9	19.1	<-33.8> 11.0	27.5	<103.0> 10.6	79.7

<Daiichi Sankyo Group>

(Billions of yen)

	FY2009									
	Q1		Q2		Q3		Q4		Full Year	
Net sales	<-3.1> 100.0	197.4	<2.2> 100.0	207.0	<-1.0> 100.0	219.1	<3.4> 100.0	181.9	<0.2> 100.0	805.5
Cost of Sales	23.0	45.4	26.2	54.3	25.4	55.6	26.0	47.3	25.2	202.6
Selling, general and administrative expenses	61.8	122.0	61.1	126.5	56.8	124.3	74.1	134.8	63.0	507.6
Research and development expenses	21.8	43.0	22.6	46.7	20.6	45.2	28.4	51.6	23.2	186.5
Other expenses	40.0	79.0	38.5	79.8	36.1	79.1	45.7	83.2	39.9	321.1
Operating income	<-24.9> 15.2	30.0	<21.3> 12.7	26.2	<-6.7> 17.9	39.1	<<> -0.1	-0.2	<11.5> 11.8	95.2
Non-operating income		2.9		2.0		1.8		0.4		7.1
Non-operating expenses		0.8		1.8		2.2		1.4		6.1
Ordinary income	<-21.3> 16.3	32.2	<40.5> 12.8	26.4	<-0.8> 17.7	38.7	<<> -0.6	-1.1	<-2.3> 11.9	96.1
Extraordinary gains		2.1		0.2		1.5		0.8		4.6
Extraordinary losses		0.7		0.3		2.5		8.1		11.6
Income before income taxes and minority interests	17.0	33.6	12.7	26.3	17.2	37.7	-4.7	-8.5	11.1	89.1
Income taxes		23.6		13.1		17.7		-0.2		54.3
Minority interests										
Net income	<-60.1> 5.1	10.0	<48.0> 6.4	13.2	<-27.9> 9.1	20.0	<<> -4.6	-8.3	<-30.2> 4.3	34.8

	FY2010							
	Q1		Q2		Q3		Q3 YTD	
Net sales	<2.1> 100.0	201.6	<-4.0> 100.0	198.8	<-2.4> 100.0	213.7	<-1.5> 100.0	614.1
Cost of Sales	22.3	44.9	27.4	54.4	25.7	55.0	25.1	154.2
Selling, general and administrative expenses	56.3	113.5	61.0	121.2	59.8	127.7	59.0	362.4
Research and development expenses	20.0	40.3	21.9	43.5	23.7	50.6	21.9	134.4
Other expenses	36.3	73.2	39.1	77.7	36.1	77.1	37.1	228.0
Operating income	<44.0> 21.5	43.3	<-11.6> 11.7	23.2	<-20.6> 14.5	31.1	<2.2> 15.9	97.5
Non-operating income		1.8		1.9		2.6		6.3
Non-operating expenses		1.7		2.0		-0.1		3.6
Ordinary income	<34.8> 21.5	43.4	<-12.6> 11.6	23.1	<-12.9> 15.8	33.7	<3.0> 16.3	100.2
Extraordinary gains		0.8		3.8		1.4		6.0
Extraordinary losses		4.2		1.0		0.7		5.9
Income before income taxes and minority interests	19.8	40.0	13.0	25.9	16.1	34.4	16.3	100.3
Income taxes		17.7		7.5		8.5		33.7
Minority interests								
Net income	<122.8> 11.1	22.3	<-39.4> 9.2	18.3	<-30.0> 12.1	26.0	<54.4> 10.8	66.6

<Ranbaxy Group>

(Billions of yen)

	FY2009									
	Q1		Q2		Q3		Q4		Full Year	
Net sales	<0.0> 100.0	29.7	<0.0> 100.0	36.4	<0.0> 100.0	36.0	<15.1> 100.0	44.5	<279.5> 100.0	146.7
Cost of Sales	57.7	17.1	56.0	20.4	55.0	19.8	40.6	18.1	51.4	75.4
Selling, general and administrative expenses	48.4	14.4	45.6	16.6	40.6	14.6	43.4	19.3	44.3	64.9
Research and development expenses	7.1	2.1	6.3	2.3	6.6	2.4	7.9	3.5	7.0	10.3
Other expenses	41.3	12.3	39.3	14.3	34.0	12.2	35.5	15.8	37.2	54.6
Operating income	<0.0> -	-1.8	<0.0> -1.6	-0.6	<0.0> 4.4	1.6	<<> 16.0	7.1	<<> 4.3	6.3
Non-operating income		1.0		9.0		2.5		8.7		21.1
Non-operating expenses		22.7		-11.9		2.9		0.7		14.5
Ordinary income	<0.0> -	-23.5	<0.0> 55.5	20.2	<0.0> 3.2	1.2	<<> 34.0	15.1	<<> 8.9	13.0
Extraordinary gains		0.0		0.0		0.0		1.3		1.3
Extraordinary losses		0.0		0.0		0.0		0.1		0.1
Income before income taxes and minority interests	-	-23.5	55.6	20.2	3.2	1.1	36.8	16.4	9.7	14.2
Income taxes		-6.6		6.0		1.3		9.2		9.8
Minority interests		0.0		0.0		0.1		0.1		0.2
Net income	<0.0> -	-16.9	<0.0> 39.1	14.2	<0.0> -0.6	-0.2	<<> 16.0	7.1	<<> 2.9	4.2

	FY2010							
	Q1		Q2		Q3		Q3 YTD	
Net sales	<84.9> 100.0	54.9	<20.1> 100.0	43.8	<-1.4> 100.0	35.5	<31.3> 100.0	134.2
Cost of Sales	35.0	19.2	45.8	20.0	54.9	19.5	43.8	58.7
Selling, general and administrative expenses	29.8	16.4	39.1	17.1	43.3	15.4	36.4	48.9
Research and development expenses	6.0	3.3	7.0	3.0	8.0	2.8	6.9	9.2
Other expenses	23.8	13.1	32.1	14.1	35.3	12.5	29.6	39.7
Operating income	<<> 35.2	19.3	<<> 15.1	6.6	<-60.0> 1.8	0.6	<<> 19.8	26.6
Non-operating income		10.0		-3.0		4.9		11.9
Non-operating expenses		1.1		2.7		0.1		3.8
Ordinary income	<<> 51.5	28.3	<-95.4> 2.1	0.9	<-374.9> 15.5	5.5	<<> 25.9	34.7
Extraordinary gains		0.0		5.2		0.0		5.2
Extraordinary losses		0.7		0.1		1.5		2.2
Income before income taxes and minority interests	50.3	27.6	13.8	6.0	11.3	4.0	28.1	37.7
Income taxes		9.2		1.5		0.1		10.8
Minority interests		0.1		0.1		0.1		0.2
Net income	<<> 33.4	18.4	<-68.3> 10.3	4.5	<<> 10.7	3.8	<<> 19.9	26.7

<Inter-Segment Transactions>

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Net sales					
Cost of Sales					
Selling, general and administrative expenses	1.5	1.5	1.5	1.5	6.0
Research and development expenses					
Other expenses	1.5	1.5	1.5	1.5	6.0
Operating income	-1.5	-1.5	-1.5	-1.5	-6.0
Non-operating income					
Non-operating expenses					
Ordinary income	-1.5	-1.5	-1.5	-1.5	-6.0
Extraordinary gains					
Extraordinary losses					
Income before income taxes and minority interests	-1.5	-1.5	-1.5	-1.5	-6.0
Income taxes	7.0	-6.4	-3.0	-11.8	-14.1
Minority interests	-8.9	7.1	0.7	6.5	5.3
Net income	0.5	-2.3	0.8	3.8	2.8

	FY2010			
	Q1	Q2	Q3	Q3 YTD
Net sales	-0.1	-0.1	-0.1	-0.2
Cost of Sales	0.0	0.0	0.1	0.1
Selling, general and administrative expenses	1.5	0.7	1.0	3.1
Research and development expenses	0.0	-0.8	-0.4	-1.3
Other expenses	1.5	1.5	1.4	4.4
Operating income	-1.5	-0.7	-1.2	-3.4
Non-operating income	0.0	-0.7	-0.1	-0.7
Non-operating expenses	0.0	0.1	0.0	0.1
Ordinary income	-1.5	-1.5	-1.3	-4.2
Extraordinary gains	0.0	-2.2	-0.5	-2.6
Extraordinary losses	0.0	0.2	0.0	0.2
Income before income taxes and minority interests	-1.5	-3.9	-1.7	-7.1
Income taxes	-0.3	-0.8	-0.6	-1.8
Minority interests	6.4	0.7	1.1	8.3
Net income	-7.6	-3.8	-2.2	-13.6

2. Currency Rate

	FY2009			
	Q1	Q2 YTD	Q3 YTD	Full Year
USD / Yen (average)	97.3	95.5	93.5	92.9
EUR / Yen (average)	132.6	133.2	133.0	131.2
INR / Yen (average)	1.89	1.95	1.95	1.95

	FY2010		
	Q1	Q2 YTD	Q3 YTD
USD / Yen (average)	92.0	89.0	86.5
EUR / Yen (average)	117.0	113.8	113.3
INR / Yen (average)	1.98	2.01	1.96

3. Sales of Global Products

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Olmesartan <antihypertensive>	<10.5>	<10.2>	<12.3>	<19.0>	<12.9>
	56.0	59.4	64.7	58.3	238.3
Olmetec (JPN)	<22.1>	<26.1>	<18.8>	<12.5>	<20.0>
	19.0	19.8	22.2	16.2	77.2
Rezaltas (JPN)	-	-	-	-	-
Benicar / Benicar HCT (US)	<-5.6>	<0.5>	<2.0>	<11.7>	<1.8>
	22.1	22.2	22.7	21.9	88.9
Azor (US)	<121.5>	<30.9>	<38.6>	<29.7>	<47.2>
	3.0	3.2	3.6	2.9	12.8
Tribenzor (US)	-	-	-	-	-
Olmetec / Olmetec Plus (EU)	<-0.2>	<-3.7>	<12.1>	<17.7>	<6.5>
	8.3	10.0	10.2	11.4	39.9
Sevikar (EU)	<->	<->	<56.5>	<156.5>	<189.3>
	0.9	1.2	2.2	2.0	6.3
Other subsidiaries / Export, etc	<29.9>	<-7.8>	<6.2>	<71.4>	<19.2>
	2.6	3.1	3.7	3.7	13.1
Levofloxacin <synthetic antibacterial>	<-23.2>	<-0.3>	<-14.2>	<-3.5>	<-10.7>
	19.8	23.5	22.1	21.8	87.2
Cravit (JPN)	<-6.8>	<26.7>	<21.0>	<17.5>	<1.5>
	9.5	11.9	10.8	11.4	43.6
Export, etc	<-49.6>	<22.7>	<17.6>	<29.5>	<31.5>
	4.8	6.4	5.1	5.0	21.3
Royalty	<-9.9>	<-19.3>	<0.7>	<-8.8>	<-9.3>
	3.7	3.2	4.1	3.6	14.6
Other subsidiaries	<-6.4>	<2.9>	<14.7>	<-2.2>	<2.2>
	1.8	2.0	2.1	1.8	7.7
Pravastatin <antihyperlipidemic>	<-8.5>	<-5.2>	<-10.8>	<-14.9>	<-9.6>
	14.7	15.0	14.8	10.5	55.0
Mevalotin (JPN)	<-8.3>	<-5.0>	<-9.1>	<-14.7>	<-8.9>
	12.4	12.4	12.8	8.5	46.2
Other subsidiaries / Export, etc.	<-10.0>	<-6.5>	<-20.2>	<-15.7>	<-12.8>
	2.3	2.6	2.0	2.0	8.8
Prasugrel (alliance revenue) <antiplatelet>	<->	<->	<->	<->	<->
	0.0	1.0	0.3	-0.7	0.5
Effient (US)	-	1.0	0.2	-1.1	0.1
Effient (EU)	<->	<->	<->	<->	<->
	0.0	0.0	0.1	0.4	0.5

	FY2010			
	Q1	Q2	Q3	Q3 YTD
Olmesartan <antihypertensive>	<7.6>	<-3.4>	<-0.8>	<-3.8>
	60.2	61.4	65.2	186.8
Olmetec (JPN)	<8.7>	<6.5>	<3.5>	<6.1>
	20.7	21.1	23.0	64.7
Rezaltas (JPN)	<->	<->	<->	<->
	1.8	0.1	1.3	3.2
Benicar / Benicar HCT (US)	<-2.9>	<-6.8>	<-9.4>	<-6.4>
	21.4	20.7	20.6	62.7
Azor (US)	<25.8>	<6.8>	<-5.3>	<8.2>
	3.8	3.4	3.5	10.7
Tribenzor (US)	-	<->	<->	<->
	-	0.7	0.5	1.2
Olmetec / Olmetec Plus (EU)	<-4.2>	<-6.7>	<-1.6>	<-4.2>
	7.9	9.3	10.1	27.3
Sevikar (EU)	<84.9>	<97.4>	<5.7>	<48.2>
	1.7	2.4	2.3	6.3
Other subsidiaries / Export, etc	<7.7>	<25.4>	<-6.2>	<8.1>
	2.8	3.9	3.5	10.2
Levofloxacin <synthetic antibacterial>	<-14.3>	<-28.0>	<-18.3>	<-20.6>
	17.0	16.9	18.1	51.9
Cravit (JPN)	<-18.3>	<-36.7>	<-14.5>	<-23.8>
	7.8	7.5	9.3	24.6
Export, etc	<-14.1>	<-29.8>	<-36.5>	<-27.2>
	4.1	4.5	3.2	11.8
Royalty	<-18.9>	<-16.4>	<-16.4>	<-17.2>
	3.0	2.7	3.4	9.1
Other subsidiaries	<15.8>	<10.6>	<-2.0>	<9.1>
	2.1	2.2	2.1	6.4
Pravastatin <antihyperlipidemic>	<-19.1>	<-21.5>	<-21.8>	<-20.8>
	11.9	11.8	11.6	35.3
Mevalotin (JPN)	<-17.9>	<-18.9>	<-22.0>	<-19.6>
	10.2	10.1	10.0	30.3
Other subsidiaries / Export, etc.	<-25.8>	<-34.1>	<-20.9>	<-27.5>
	1.7	1.7	1.6	5.0
Prasugrel (alliance revenue) <antiplatelet>	<->	<->	<->	<->
	0.8	1.0	1.5	3.3
Effient (US)	<->	<->	<->	<->
	0.4	0.8	1.1	2.2
Effient (EU)	<->	<->	<->	<->
	0.4	0.2	0.4	1.1

4. Overseas Sales

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Overseas sales	<23.9> 109.8	<42.6> 122.7	<43.9> 120.6	<12.6> 129.2	<29.2> 482.3	<22.0> 134.0	<1.6> 124.7	<-4.0> 115.8	<6.0> 374.4
Overseas sales ratio	48.4%	50.4%	47.3%	57.0%	50.7%	52.2%	51.4%	46.5%	50.1%
North America	<1.1> 58.9	<16.6> 62.5	<11.5> 58.9	<18.1> 66.9	<11.7> 247.2	<31.7> 77.6	<8.4> 67.8	<-0.3> 58.7	<13.2> 204.1
Europe	<21.3> 27.2	<27.6> 29.7	<32.9> 29.2	<3.0> 31.5	<19.7> 117.5	<-12.4> 23.8	<-12.6> 26.0	<-7.4> 27.0	<-10.8> 76.8
Other	<197.4> 23.7	<232.9> 30.5	<289.4> 32.5	<11.8> 30.8	<118.7> 117.6	<37.4> 32.6	<1.3> 30.9	<-7.6> 30.1	<7.8> 93.6

5. Geographic Segment Information

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Net Sales	<11.5> 227.1	<20.2> 243.4	<15.3> 255.1	<5.6> 226.4	<13.1> 952.1	<12.9> 256.4	<-0.4> 242.5	<-2.3> 249.2	<3.1> 748.1
Japan	<-3.1> 128.5	<1.8> 135.4	<-3.3> 146.4	<-3.1> 109.2	<-1.9> 519.4	<3.1> 132.5	<-5.8> 127.6	<-2.5> 142.6	<-1.8> 402.7
North America	<7.0> 54.2	<20.4> 54.5	<15.6> 53.1	<24.1> 60.7	<16.6> 222.5	<33.2> 72.2	<15.3> 62.8	<2.1> 54.2	<17.0> 189.3
Europe	<48.1> 22.5	<32.4> 24.5	<37.8> 24.8	<6.7> 27.5	<28.2> 99.3	<-8.1> 20.6	<-7.9> 22.5	<-3.8> 23.9	<-6.5> 67.1
India	<-> 11.5	<-> 16.5	<-> 16.8	<-1.1> 15.1	<292.8> 59.9	<67.9> 19.3	<-2.2> 16.1	<-9.7> 15.2	<12.9> 50.6
Other	<99.7> 10.5	<115.3> 12.6	<136.2> 13.9	<17.5> 14.0	<76.4> 51.0	<12.1> 11.7	<6.3> 13.4	<-5.3> 13.2	<3.6> 38.3
Operating Income	<-33.1> 26.8	<11.5> 24.1	<7.6> 39.2	<-> 5.4	<7.5> 95.5	<128.1> 61.1	<20.6> 29.0	<-22.2> 30.5	<33.9> 120.6
Japan	15.6	11.9	22.9	-9.9	40.5	35.0	13.9	17.8	66.7
North America	13.9	13.0	12.4	7.7	47.1	16.0	7.3	8.4	31.8
Europe	1.2	1.9	3.1	3.0	9.1	2.1	2.5	3.2	7.9
India	-3.2	-1.7	3.1	6.3	4.5	15.2	0.5	-1.1	14.5
Other	0.9	0.5	2.2	-0.2	3.3	1.0	0.9	1.9	3.8

6. Status of Major Companies

Data available at www.daiichisankyo.com/ir/financial/index.html

6-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Total net sales of ethical pharmaceuticals	<3.7>	<5.3>	<1.4>	<1.9>	<1.4>	<0.6>	<1.7>	<1.4>	<0.8>
	104.6	104.8	118.4	84.5	412.3	105.3	103.0	116.8	325.1
Olmetec <antihypertensive>	<22.1>	<26.1>	<18.8>	<12.5>	<20.0>	<8.7>	<6.5>	<3.5>	<6.1>
	19.0	19.8	22.2	16.2	77.2	20.7	21.1	23.0	64.7
Rezallas <antihypertensive>	-	-	-	-	-	<>	<>	<>	<>
	-	-	-	-	-	1.8	0.1	1.3	3.2
Calblock <antihypertensive>	<14.5>	<18.9>	<12.5>	<4.7>	<12.8>	<6.5>	<0.6>	<0.6>	<2.1>
	3.5	3.5	3.8	2.9	13.7	3.7	3.5	3.8	11.0
Artist <antihypertensive>	<6.3>	<11.3>	<6.0>	<1.9>	<6.5>	<1.8>	<1.6>	<0.9>	<0.3>
	6.0	5.9	6.4	5.0	23.3	6.1	5.8	6.3	18.3
Mevalotin <antihyperlipidemic agent>	<-8.3>	<-5.0>	<-9.1>	<-14.7>	<-8.9>	<-17.9>	<-18.9>	<-22.0>	<-19.6>
	12.4	12.4	12.8	8.5	46.2	10.2	10.1	10.0	30.3
Kremezin <treatment for chronic renal failure>	<5.5>	<8.8>	<4.3>	<-0.5>	<4.7>	<5.5>	<-0.9>	<-1.0>	<1.1>
	3.4	3.5	3.7	2.8	13.3	3.5	3.5	3.6	10.7
Hanp <treatment for acute cardiac failure>	<1.5>	<11.3>	<-4.8>	<7.5>	<3.0>	<-0.2>	<-8.4>	<-1.4>	<-3.0>
	2.4	2.1	2.6	2.3	9.4	2.4	1.9	2.6	6.9
Livalo <antihyperlipidemic agent>	<22.8>	<25.9>	<18.8>	<10.5>	<19.6>	<9.9>	<7.9>	<5.8>	<7.8>
	1.8	1.8	2.1	1.6	7.3	2.0	2.0	2.2	6.2
Sunrythm <antiarrhythmic agent>	<-1.2>	<3.4>	<-0.8>	<-7.5>	<-1.3>	<-5.0>	<-9.5>	<-10.1>	<-8.2>
	3.0	3.0	3.2	2.3	11.5	2.9	2.7	2.9	8.4
Fastic <antidiabetic agent>	<1.8>	<7.3>	<-0.1>	<-6.4>	<0.9>	<-3.8>	<-9.4>	<-11.5>	<-8.3>
	1.4	1.4	1.4	1.0	5.2	1.3	1.3	1.3	3.8
Cravit <synthetic antibacterial agent>	<-6.8>	<26.7>	<-21.0>	<-17.5>	<1.5>	<-18.3>	<-36.7>	<-14.5>	<-23.8>
	9.5	11.9	10.8	11.4	43.6	7.8	7.5	9.3	24.6
Inavir <anti-influenza>	-	-	-	-	-	-	-	<>	<>
	-	-	-	-	-	-	-	2.8	2.8
Loxonin <anti-inflammatory analgesic>	<33.0>	<19.7>	<16.0>	<19.4>	<21.4>	<15.9>	<11.0>	<10.0>	<12.1>
	11.2	12.5	13.3	9.9	47.0	13.0	13.9	14.7	41.5
Urief <treatment for dysuria>	<26.6>	<26.1>	<19.3>	<-9.9>	<14.3>	<11.2>	<9.2>	<9.2>	<9.8>
	2.2	2.2	2.6	2.0	9.0	2.5	2.5	2.8	7.7
Zyrtec <antiallergic agent>	<18.4>	<13.3>	<8.8>	<-15.1>	<2.7>	<-14.3>	<-0.9>	<-0.3>	<-5.5>
	2.4	1.8	2.4	3.0	9.6	2.1	1.8	2.4	6.2
Omnipace <contrast agent>	<-2.0>	<3.4>	<-10.8>	<-4.8>	<-3.7>	<-10.1>	<-12.4>	<-8.5>	<-10.4>
	7.1	7.5	7.1	5.5	27.3	6.4	6.6	6.5	19.5

6-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Daiichi Sankyo Healthcare Co., Ltd	<-6.9>	<-2.1>	<-8.2>	<-14.1>	<-7.4>	<-2.7>	<-12.9>	<-9.1>	<-2.5>
	9.5	13.5	12.1	8.6	43.7	9.3	11.7	13.2	34.2
LuLu Series	<-2.4>	<18.9>	<-19.5>	<12.8>	<1.5>	<37.0>	<-18.9>	<47.0>	<11.6>
	1.2	4.3	2.8	1.6	9.9	1.7	3.5	4.2	9.3
Gaster 10	<-29.1>	<-45.7>	<-38.9>	<-31.1>	<-37.0>	<-8.5>	<2.5>	<-2.7>	<-3.0>
	0.5	0.5	0.6	0.5	2.1	0.5	0.5	0.6	1.6
Daiichi Sankyo Ichoyaku series	<26.3>	<-1.1>	<2.8>	<7.9>	<7.8>	<-6.9>	<-13.4>	<-9.5>	<-3.1>
	0.9	0.9	1.0	0.8	3.5	0.8	0.8	1.1	2.7
Patecs series	<15.3>	<-17.8>	<-25.9>	<-11.6>	<-9.3>	<-37.0>	<-1.3>	<-3.2>	<-17.4>
	0.9	0.6	0.5	0.4	2.4	0.6	0.6	0.5	1.7
Transino	<-62.3>	<-72.0>	<-37.4>	<-96.4>	<-39.9>	<-13.4>	<-1.7>	<-57.6>	<-26.1>
	0.3	0.2	0.2	0.3	0.9	0.2	0.1	0.1	0.5

6-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Daiichi Sankyo, Inc. (DSI)	<-11.2>	<5.6>	<5.8>	<15.2>	<2.9>	<1.7>	<1.2>	<0.6>	<1.2>
	33.0	33.5	34.4	32.1	133.0	33.6	33.9	34.6	102.1
mil USD	<-4.6>	<21.7>	<13.4>	<18.0>	<11.4>	<7.6>	<10.2>	<10.3>	<9.4>
	339	357	382	354	1,433	365	394	422	1,180
Benicar / Benicar HCT <antihypertensive>	<-5.6>	<0.5>	<2.0>	<11.7>	<1.8>	<-2.9>	<-6.8>	<-9.4>	<-6.4>
	22.1	22.2	22.7	21.9	88.9	21.4	20.7	20.6	62.7
mil USD	<1.4>	<15.6>	<9.7>	<14.8>	<10.2>	<2.7>	<1.6>	<-0.5>	<1.2>
	227	237	253	242	958	233	241	251	725
Azor <antihypertensive>	<121.5>	<30.9>	<-38.6>	<29.7>	<47.2>	<25.8>	<-6.8>	<-5.3>	<8.2>
	3.0	3.2	3.6	2.9	12.8	3.8	3.4	3.5	10.7
mil USD	<138.0>	<49.3>	<50.9>	<35.4>	<59.4>	<33.1>	<16.9>	<4.6>	<17.0>
	31	34	40	32	138	42	39	42	123
Tribenzor <antihypertensive>	-	-	-	-	-	<>	<>	<>	<>
	-	-	-	-	-	<>	0.7	0.5	1.2
mil USD	-	-	-	-	-	-	7	6	13
Welchol <antihyperlipidemic / type 2 diabetes>	<7.0>	<6.6>	<10.2>	<28.2>	<12.4>	<1.8>	<13.4>	<7.6>	<7.5>
	6.9	6.5	7.3	6.8	27.5	7.0	7.4	7.9	22.2
mil USD	<14.9>	<22.8>	<18.7>	<31.4>	<21.7>	<7.6>	<23.1>	<17.8>	<16.2>
	71	69	81	75	296	76	85	95	257
Effient (alliance revenue) <antiplatelet>	-	<>	<>	<>	<>	<>	<>	<>	<>
	-	1.0	0.2	-1.1	0.1	0.4	0.8	1.1	2.2
mil USD	<>	<>	<>	<>	<>	<>	<>	<>	<>
	-	10	2	-11	1	4	9	13	25

6-4. Luitpold Pharmaceuticals, Inc. (US)

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Luitpold Pharmaceuticals, Inc. (LPI)	<-1.1>	<-0.4>	<-6.4>	<-18.9>	<-1.9>	<-10.4>	<-1.3>	<-8.5>	<-1.2>
	13.4	13.5	12.6	12.7	52.1	14.7	13.7	11.5	39.9
mil USD	<-6.2>	<-14.5>	<-1.1>	<-21.4>	<-10.3>	<-16.7>	<-10.6>	<-1.2>	<-9.5>
	137	144	140	140	561	160	159	142	461
Venofer <treatment for iron deficiency anemia>	<-3.9>	<-4.6>	<-4.1>	<-17.0>	<-0.3>	<-5.2>	<-5.0>	<-27.1>	<-8.9>
	8.0	8.1	8.0	8.0	32.2	8.4	7.7	5.8	22.0
mil USD	<-3.2>	<-9.6>	<-3.3>	<-19.8>	<-8.6>	<-11.3>	<-3.8>	<-18.5>	<-1.5>
	82	87	89	89	346	92	90	72	254

6-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Daiichi Sankyo Europe GmbH (DSE)	<-14.1>	<-0.4>	<-6.1>	<-9.7>	<-7.1>	<-14.6>	<-10.0>	<-5.0>	<-9.7>
	17.3	18.4	19.1	20.4	75.2	14.8	16.6	18.1	49.5
mil €	<-40.6>	<-20.8>	<-5.9>	<-9.8>	<-17.1>	<-3.2>	<-8.3>	<-12.1>	<-6.0>
	131	138	144	161	574	126	149	161	437
Olmotec / Olmetec Plus <antihypertensive>	<-0.2>	<-3.7>	<-12.1>	<-17.7>	<-6.5>	<-4.2>	<-6.7>	<-1.6>	<-4.2>
	8.3	10.0	10.2	11.4	39.9	7.9	9.3	10.1	27.3
mil €	<-23.0>	<-16.7>	<-10.6>	<-17.2>	<-16.5>	<-8.5>	<-12.0>	<-16.1>	<-12.5>
	63	74	77	90	304	68	83	90	241
Sevikar <antihypertensive>	<>	<>	<-56.5>	<-156.5>	<-189.3>	<-84.9>	<-97.4>	<-5.7>	<-48.2>
	0.9	1.2	2.2	2.0	6.3	1.7	2.4	2.3	6.3
mil €	<>	<>	<-77.6>	<-166.6>	<-216.5>	<-109.5>	<-136.0>	<-24.9>	<-73.9>
	7	9	16	16	48	14	21	20	56
Evista <treatment for osteoporosis>	<-24.9>	<-27.5>	<-31.1>	<-4.6>	<-23.6>	<-29.6>	<-36.8>	<-21.7>	<-29.9>
	2.4	2.6	2.1	2.1	9.2	1.7	1.6	1.6	5.0
mil €	<-7.5>	<-12.2>	<-32.8>	<-10.1>	<-16.4>	<-20.2>	<-23.6>	<-7.4>	<-17.7>
	18	19	16	17	70	15	15	15	44

Alliance Revenue of Efient (Europe)

Efient <antiplatelet>	<>	<>	<>	<>	<>	<>	<>	<>	<>
	0.0	0.0	0.1	0.4	0.5	0.4	0.2	0.4	1.1
mil USD	<>	<>	<>	<>	<>	<>	<>	<>	<>
	0	0	1	4	5	5	3	5	13

Alliance Revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include Alliance Revenue of Efient (Europe).

6-6. Asia, South and Central America (ASCA)

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
ASCA Total	<-0.5>	<-7.1>	<-11.7>	<-27.5>	<-12.1>	<-12.7>	<-12.8>	<-3.3>	<-9.3>
	5.3	6.3	6.6	7.7	25.8	5.9	7.1	6.8	19.8
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<-4.3>	<-7.6>	<-3.1>	<-1.4>	<-2.0>	<-17.8>	<-3.6>	<-6.3>	<-4.3>
	1.0	1.1	1.1	0.9	4.1	1.1	1.1	1.1	3.3
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<-48.0>	<-40.2>	<-35.2>	<-34.0>	<-38.4>	<-35.5>	<-32.5>	<-10.5>	<-25.0>
	1.1	1.3	1.4	1.5	5.3	1.4	1.7	1.6	4.8
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-8.6>	<-14.9>	<-14.4>	<-4.5>	<-10.7>	<-8.6>	<-1.0>	<-13.5>	<-1.2>
	0.9	0.8	0.7	0.7	3.1	0.8	0.8	0.8	2.4
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<-15.6>	<-2.1>	<-56.8>	<-38.9>	<-13.7>	<-31.4>	<-2.9>	<-9.7>	<-13.8>
	0.8	0.9	0.9	0.9	3.4	1.0	0.9	1.0	2.9
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-0.9>	<-0.4>	<-4.2>	<-27.4>	<-7.7>	<-35.8>	<-22.8>	<-53.4>	<-36.7>
	0.2	0.2	0.2	0.3	0.9	0.2	0.3	0.3	0.8
Daiichi Sankyo Brasil Farmacéutica Ltda. (DSBR)	<-25.5>	<-12.7>	<-7.2>	<-18.4>	<-5.2>	<-36.5>	<-39.5>	<-6.4>	<-24.7>
	0.8	1.0	1.3	1.6	4.7	1.0	1.4	1.4	3.9
Daiichi Sankyo Venezuela, S.A. (DSVE)	<-35.3>	<-45.0>	<-20.7>	<-76.3>	<-47.9>	<-46.7>	<-18.7>	<-25.1>	<-28.9>
	0.7	0.9	0.8	1.7	4.1	0.4	0.7	0.6	1.7

6-7. Ranbaxy Laboratories Limited

(Billions of yen)

	FY2009					FY2010			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Ranbaxy Laboratories Limited (RLL)	<>	<>	<>	<-14.9>	<-279.3>	<-84.7>	<-19.9>	<-1.6>	<-31.1>
	29.7	36.4	36.0	44.4	146.6	54.8	43.7	35.4	134.0

(This page is intentionally left blank)

